| Melissa Janelle Davey, CRNA | |
|
1 Medical Center Dr, Dhmc, Department Of Anesthesiology, Lebanon, NH 03756-1000 | |
| (603) 650-5922 | |
| Not Available |
| Full Name | Melissa Janelle Davey |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 14 Years |
| Location | 1 Medical Center Dr, Lebanon, New Hampshire |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154628295 | NPI | - | NPPES |
| 1018793 | Medicaid | VT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 063990-23 (New Hampshire) | Secondary |
| 367500000X | Nurse Anesthetist, Certified Registered | AP124025 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ascension Seton Medical Center Austin | Austin, TX | Hospital |
| Cedar Park Regional Medical Center | Cedar park, TX | Hospital |
| Seton Northwest Hospital | Austin, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| U S Anesthesia Partners Of Texas, Pa | 7315850351 | 2379 |
News Archive
Even though babies at six months have just about got the hang of sitting up but cannot yet walk or talk, it seems they nevertheless have the ability to discern who is nice and who is not.
In a landmark agreement at the G7 summit, held in Cornwall, the United Kingdom of Great Britain and Northern Ireland, global leaders have pledged to share COVID-19 vaccine doses internationally, in support of global equitable access and to help end the acute phase of the pandemic.
Isis Pharmaceuticals, Inc. announced the initiation of a Phase 1 study of ISIS-FXIRx, an antisense drug designed to treat clotting disorders. ISIS-FXIRx inhibits the production of Factor XI, a clotting factor that is an important component of the coagulation pathway. Because of its role in the intrinsic coagulation pathway, inhibition of Factor XI could offer an effective approach for preventing the formation of blood clots with a lower risk of bleeding.
On May 12, the U.S. House again passed the AMA-supported Health Act (H.R. 4280) by a vote of 229-197, bringing America's patients and physicians one step closer to relief from the current broken medical liability system.
A recent study by researchers from the United Kingdom (UK) revealed that antibody levels associated with protection against reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are likely to last from 1.5 to 2 years on average and that the protection from severe infection may be present for several years.
› Verified 9 days ago
| Entity Name | U S Anesthesia Partners Of Texas, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548208564 PECOS PAC ID: 7315850351 Enrollment ID: O20031106000563 |
News Archive
Even though babies at six months have just about got the hang of sitting up but cannot yet walk or talk, it seems they nevertheless have the ability to discern who is nice and who is not.
In a landmark agreement at the G7 summit, held in Cornwall, the United Kingdom of Great Britain and Northern Ireland, global leaders have pledged to share COVID-19 vaccine doses internationally, in support of global equitable access and to help end the acute phase of the pandemic.
Isis Pharmaceuticals, Inc. announced the initiation of a Phase 1 study of ISIS-FXIRx, an antisense drug designed to treat clotting disorders. ISIS-FXIRx inhibits the production of Factor XI, a clotting factor that is an important component of the coagulation pathway. Because of its role in the intrinsic coagulation pathway, inhibition of Factor XI could offer an effective approach for preventing the formation of blood clots with a lower risk of bleeding.
On May 12, the U.S. House again passed the AMA-supported Health Act (H.R. 4280) by a vote of 229-197, bringing America's patients and physicians one step closer to relief from the current broken medical liability system.
A recent study by researchers from the United Kingdom (UK) revealed that antibody levels associated with protection against reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are likely to last from 1.5 to 2 years on average and that the protection from severe infection may be present for several years.
› Verified 9 days ago
| Entity Name | Cardiovascular Anesthesiology,p.a. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316029325 PECOS PAC ID: 3173580867 Enrollment ID: O20041214000886 |
News Archive
Even though babies at six months have just about got the hang of sitting up but cannot yet walk or talk, it seems they nevertheless have the ability to discern who is nice and who is not.
In a landmark agreement at the G7 summit, held in Cornwall, the United Kingdom of Great Britain and Northern Ireland, global leaders have pledged to share COVID-19 vaccine doses internationally, in support of global equitable access and to help end the acute phase of the pandemic.
Isis Pharmaceuticals, Inc. announced the initiation of a Phase 1 study of ISIS-FXIRx, an antisense drug designed to treat clotting disorders. ISIS-FXIRx inhibits the production of Factor XI, a clotting factor that is an important component of the coagulation pathway. Because of its role in the intrinsic coagulation pathway, inhibition of Factor XI could offer an effective approach for preventing the formation of blood clots with a lower risk of bleeding.
On May 12, the U.S. House again passed the AMA-supported Health Act (H.R. 4280) by a vote of 229-197, bringing America's patients and physicians one step closer to relief from the current broken medical liability system.
A recent study by researchers from the United Kingdom (UK) revealed that antibody levels associated with protection against reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are likely to last from 1.5 to 2 years on average and that the protection from severe infection may be present for several years.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Melissa Janelle Davey, CRNA Po Box 840853, Dallas, TX 75284-0853 Ph: (972) 233-1999 | Melissa Janelle Davey, CRNA 1 Medical Center Dr, Dhmc, Department Of Anesthesiology, Lebanon, NH 03756-1000 Ph: (603) 650-5922 |
News Archive
Even though babies at six months have just about got the hang of sitting up but cannot yet walk or talk, it seems they nevertheless have the ability to discern who is nice and who is not.
In a landmark agreement at the G7 summit, held in Cornwall, the United Kingdom of Great Britain and Northern Ireland, global leaders have pledged to share COVID-19 vaccine doses internationally, in support of global equitable access and to help end the acute phase of the pandemic.
Isis Pharmaceuticals, Inc. announced the initiation of a Phase 1 study of ISIS-FXIRx, an antisense drug designed to treat clotting disorders. ISIS-FXIRx inhibits the production of Factor XI, a clotting factor that is an important component of the coagulation pathway. Because of its role in the intrinsic coagulation pathway, inhibition of Factor XI could offer an effective approach for preventing the formation of blood clots with a lower risk of bleeding.
On May 12, the U.S. House again passed the AMA-supported Health Act (H.R. 4280) by a vote of 229-197, bringing America's patients and physicians one step closer to relief from the current broken medical liability system.
A recent study by researchers from the United Kingdom (UK) revealed that antibody levels associated with protection against reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are likely to last from 1.5 to 2 years on average and that the protection from severe infection may be present for several years.
› Verified 9 days ago
Patrick C Keane, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Lebanon, NH 03756 Phone: 215-589-0469 | |
Frederic Jon Schaafsma, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 1 Medical Center Dr, Lebanon, NH 03756 Phone: 603-650-5922 | |
Jeffrey C. Horstman, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Lebanon, NH 03756 Phone: 603-650-5922 | |
Sarah Marie Zack Hewitt, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Anesthesiology, Lebanon, NH 03756 Phone: 603-650-5922 | |
Mr. Gustaaf C Vansoestbergen, CRNA MSN MPA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 1 Medical Center Dr, Lebanon, NH 03756 Phone: 603-650-5922 | |
Mr. Thomas Reyes Iv, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: One Medical Center Drive, Anesthesiology, Lebanon, NH 03756 Phone: 603-650-5922 | |
Ms. Katy Ann Taylor, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1 Medical Center Dr, Lebanon, NH 03756 Phone: 603-650-5922 |